Pathos AI vs Oura

About

Pathos AI is a clinical-stage AI company building the world's largest multimodal oncology AI platform, combining pathology imaging, genomics, clinical records, and treatment outcome data to power precision cancer care. Founded by oncologists, pathologists, and AI researchers, Pathos has assembled a dataset at a scale that gives its models a meaningful edge: by ingesting vast quantities of multimodal cancer data, its platform can predict treatment responses, identify biomarkers, and guide therapy selection with a level of accuracy that single-modality systems cannot match.\n\nThe platform serves oncologists and cancer centers by providing AI-augmented pathology reads, treatment outcome predictions, and clinical trial matching. Pathos's AI can analyze whole-slide pathology images in combination with molecular and clinical data to generate insights that inform diagnosis and treatment decisions. The company has also built partnerships with pharmaceutical companies — including Novo Nordisk and Prelude Therapeutics — to use its platform for drug development and clinical trial design, adding a biopharma revenue stream alongside its clinical business.\n\nPathos raised $365M in a Series D round at a $1.6B valuation, bringing total funding to $467M. The Series D was one of the largest oncology AI fundraises in history and included backing from top-tier life sciences investors. The Novo Nordisk and Prelude partnerships validate the platform's scientific depth and its utility across both clinical care and drug development. As of 2025–2026, Pathos is advancing toward direct clinical deployment and regulatory submissions, positioning itself as a core infrastructure layer for the future of AI-guided cancer treatment.